Evaluating the efficacy of basiliximab versus no induction in low-immunological-risk kidney transplant recipients: a propensity score matched analysis.

Ren Fail · 2025 · PMC11843659 · PMID 39978365

Europe PMC DOI

hedged sentence

0.1770

closest p · 3.5× alpha

0.1770

boldest claim

The sentences

did not reach statistical significancep = 0.177not close (p > 0.1)

Delayed graft function (DGF) During follow-up, 33 recipients (18.1%) experienced DGF, with a lower incidence in the no induction group (9.76%, 4/41) compared to the BSX group (20.6%, 29/141), although the difference did not reach statistical significance ( p = 0.177, Table S6 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.